Slides
Page 1
03 February 2026 FY 2025 – Preliminary Unaudited Revenue SUSTAINABLE INNOVATION, WORLD -CLASS SURGEON EDUCATION, AND AN UNWAVERING COMMITMENT TO IMPROVING PATIENT OUTCOMES
Page 2
2 This presentation (the “Presentation”) has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at https://www.medacta.com/EN/investors. FORWARD-LOOKING INFORMATION This Presentation has been prepared by Medacta and may include forward-looking information and statements concerning the outlook for our business. These statements are based on current expectations, estimates and projections about the factors that may affect our future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as “expects”, “believes”, “estimates”, “targets”, “plans”, “outlook” or similar expressions. There are numerous risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from the forward-looking information and statements made in this Presentation. The important factors that could cause such differences include: changes in the global economic conditions and the economic conditions of the regions and markets in which the Group operates; changes in healthcare regulations (in particular with regard to medical devices); the development of our customer base; the competitive environment in which the Group operates; manufacturing or logistics disruptions; the impact of fluctuations in foreign exchange rates; and such other factors as may be discussed from time to time. Although we believe that our expectations reflected in any such forward-looking statement are based upon reasonable assumptions, we can give no assurance that those expectations will be achieved. ALTERNATIVEPERFORMANCE MEASURES This Presentation may contain information regarding alternative performance measures. Definitions of these measures may be found on the financial reports available on our website at https://www.medacta.com/EN/investors. THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF MEDACTA OR THE GROUP Not all productsare availablein all countries.Productavailabilityis dependentupon the registrationrequirements for your country. All trademarks and registered trademarks are the property of their respective owners. Disclaimer Related Trademarks Medacta Group Related Trademarks are registered at least in Switzerland. The products and services listed below may not be all-inclusive, and other Medacta products and services not listed below may be covered by one or more trademarks. The below products and services may be covered by additional trademarks not listed below. Note that Swiss trademarks may have foreign counterparts. AMIS®, GMK® SpheriKA, MyShoulder®, MyKA , NextAR , NextAR Spine.
Page 3
FRANCESCO SICCARDI Chief Executive Officer
Page 4
4 Continued significant above-market growth FY 2025 revenue* in EUR 683.8 m FY 2025 revenue* growth 18.5 % in cc ** 15.8 % in EUR Team expansion 258 new employees to increase network of surgeons & foster further growth Education and personalized training of surgeons thereby acquiring new surgeons across all business lines Differentiating innovations with aim to improve patient outcomes & healthcare sustainability Notes * Unaudited figures ** Constant currency Definitions of Alternative Performance Measures can be found in our 2024 Annual Report, available on our website: https://www.medacta.com/EN/investors
Page 5
5 Continued high teens revenue growth • FY 2025 revenue growth* of 18.5% yoy • Outgrowingmarket**by 4.3x • Revenue CAGR* (FY 2021 - FY 2025) of 17.4% Notes • In constant currency ** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025 0 100 200 300 400 500 600 700 2021 2022 2023 2024 2025 Revenue in EUR m
Page 6
6 Medacta’s success pillars for above-market growth Team expansion to increase network of surgeons & foster further growth Differentiating innovations with aim to improve patient outcomes & healthcare sustainability Education and personalized training of surgeons thereby acquiring new surgeons across all business lines 1 2 3
Page 7
7 Substantial growth across all geographies Notes * In constant currency Abbreviations: EMEA: Europe, Middle East and Africa; NORAM: North America; APAC: Asia Pacific; LATAM: Latin America • NORAM and APAC surging respectively, 19.0% and 23.0% yoy • EMEA: outstanding above-market growth in mid-teens • LATAM: growing more than 40% yoy FY 2025 geographic revenue distribution 18.5%* 590.6 699.6 683.8 43.2 34.1 26.5 5.2 -15.7 FY 2024 EMEA NORAM APAC LATAM FY 2025 in cc* FX FY 2025 Revenue in EUR m 15.2% 19.0% 23.0% 42.2% Growth rate in constant currency EMEA EUR 327.5m, 48%NORAM EUR 204.5m, 30% APAC EUR 134.8m, 20% LATAM EUR 17.0m, 2%
Page 8
8 Excellent above-market growth across all business lines 18.5%* Notes * In constant currency ** Extremities includes Shoulder and Sportsmed FY 2025 revenue distribution by business line Hip, EUR 270.5m, 40% Knee EUR 284.1m, 42% Extremities** EUR 72.1m, 10% Spine EUR 57.0m, 8%590.6 699.6 683.8 29.5 49.9 23.2 6.3 -15.7 Revenue in EUR m 11.9% 20.7% 46.2% 12.2% Growth rate in constant currency
Page 9
9 Continued double-digit growth in Hip Hip – FY 2025 • Growth mainly attributable to Medacta’s Anterior Minimally Invasive Surgery (AMIS) platform • Outstanding growth in APAC and NORAM • Almost 3 x above-market growth 2025E** yoy Notes * In constant currency ** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025 0 50 100 150 200 250 300 2021 2022 2023 2024 2025 Revenue in EUR m
Page 10
10 Excellent expansion in Knee Notes * In constant currency ** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025 0 50 100 150 200 250 300 2021 2022 2023 2024 2025 Revenue in EUR m Knee – FY 2025 • Outstanding performance due to GMK SpheriKA and MyKA, Medacta’s personalized Kinematic Alignment platform • NORAM and EMEA grew in low twenties, closely followed by APAC • 4.6x above-market growth 2025E** yoy
Page 11
11 Outstanding growth in Spine Spine – FY 2025 • Solid revenue growth strongly supported by Medacta’s technologies, particularly by NextAR Spine and the NextAR Rod Optimizer • Particularly strong performance in EMEA, followed by APAC • 3.5x above-market growth 2025E** yoy Selection of pre-contoured rods Notes * In constant currency ** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025 0 10 20 30 40 50 60 70 2021 2022 2023 2024 2025 Revenue in EUR m
Page 12
12 Continued superior growth in Extremities Extremities – FY 2025 • Expansion primarily due to Medacta Shoulder System, supported by advanced technologies such as MyShoulder and NextAR • Sportsmed portfolio strengthened with acquisition of Parcus • 3.5x above-market growth 2025E** yoy in Shoulder and more than 3x in Sportsmed (organic) Notes * In constant currency ** The Orthopaedic Industry Annual Report® published by Orthoworld® Inc., published May 2025 0 10 20 30 40 50 60 70 80 2021 2022 2023 2024 2025 Revenue in EUR m
Page 13
13 Outlook Outlook 2025 Medacta is targeting a revenue growth in the range of 16% to 18% in constant currency and an adjusted EBITDA margin of around 28% before any currency effects, including the recent Parcus acquisition,subjectto unforeseenevents. Mid-term outlook Revenuecompoundannual growth rate (CAGR) (2024-2027E) in constantcurrencyis expectedto be in the range of 10% to 14%, and an adjusted EBITDA margin targeted to be around 28% before any currencyeffects. Tariffs Medacta remains not impacted by the US tariffs and will continue to monitor the development. Notes Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency”, “EBITDA”, “adjusted EBITDA”, “Free Cash Flow”, “adjusted Free Cash Flow”, “Net Debt” and “Leverage”. These Alternative Performance Measures (APMs) should be regarded as complementary information to, and not as a substitute for the IFRS performance measures. For definitions of APMs, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed “Alternative Performance Measures” of the 2025 Half-Year Report. The 2025 Half-Year Report is available and can be accessed at: https://www.medacta.com/EN/financial-reports-and-presentations
Page 14
14 Key Messages • Excellent continued above-market FY 2025 revenue growth of 18.5% yoy in constantcurrencyas result of • Differentiating innovations to improve patient outcomes and healthcaresustainability • Education and personalized training of surgeons • Further expansion of sales reps and team • Our aim: Continuingto outgrow the market Notes Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency”, “EBITDA”, “adjusted EBITDA”, “Free Cash Flow”, “adjusted Free Cash Flow”, “Net Debt” and “Leverage”. These Alternative Performance Measures (APMs) should be regarded as complementary information to, and not as a substitute for the IFRS performance measures. For definitions of APMs, together with reconciliations to the most directly reconcilable IFRS line items, please refer section headed “Alternative Performance Measures” of the 2025 Half-Year Report. The 2025 Half-Year Report is available and can be accessed at: https://www.medacta.com/EN/financial-reports-and-presentations
Page 15
Thank you to all our employees, clients, suppliers and partners worldwide